Repros Therapeutics Inc. is expected to report second-quarter 2017 results on Aug 8. Let’s see how things are shaping up for this quarter.
Repros Therapeutics’ share price has plunged 73.8% year to date, while the industry has gained 9.9%.
With no approved products in its portfolio yet, investors are expected to remain focused on Repros’ pipeline-related updates. The company’s pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros’ pipeline is enclomiphene, currently under review in the EU and the U.S. The company intends to get the candidate approved of for the treatment of secondary hypogonadism. A decision in the EU should be out in the third quarter of 2017.
Repros’ second candidate, Proellex, is being evaluated in phase II orally administered trials for treatment of endometriosis and uterine fibroids. Last month, the company announced that it has received a preliminary feedback from the FDA regarding the clinical development program for Proellex to treat uterine fibroids by oral mechanism.
Per the FDA’s review, Proellex will remain on partial clinical hold and the company will be required to accumulate a large pre-approval safety database for the candidate to be evaluated further. To meet the FDA’s requirement, the company is supposed to conduct a much bigger clinical study, expected to be time-consuming as well as expensive.
We remind investors that Proellex’s studies on oral dose for treating endometriosis and uterine fibroids were placed under clinical hold in 2009. But later, the FDA allowed the studies to carry on under a partial clinical hold with low oral dosage.
The company is also evaluating Proellex in a phase IIb examination for uterine fibroids by vaginal delivery. However, this study has no clinical hold issues and last November, the company presented some positive topline data from the same.
Repros Therapeutics currently carries a Zacks Rank #3 (Hold).
Stocks That Warrant a Look
Per our model, here are some health care stocks worth considering, as all have the right combination of elements – a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) – to come up with an earnings beat this quarter:
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) is expected to release results on Aug 8 with an Earnings ESP of +9.88% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arena Pharmaceuticals, Inc. (ARNA - Free Report) is scheduled to release results on Aug 7. The company has an Earnings ESP of +5.88% and a Zacks Rank #2.
Puma Biotechnology, Inc. (PBYI - Free Report) is expected to release results on Aug 8. The company has an Earnings ESP of +3.33% and a Zacks Rank #3.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>